

11. [AMENDED] The composition of claim 8, wherein M is an antigen, and the composition is [An] immunogenic [composition comprising lactadherin or a variant thereof in association with an antigen].

12. [AMENDED] A variant of lactadherin, wherein said variant lacks one or more protein features selected from the groups consisting of a functional phospholipid binding site [and/or] and a functional integrin binding site.

13. [AMENDED] A chimeric protein comprising the polypeptide sequence of lactadherin or a variant thereof fused to a polypeptide sequence.

14. [AMENDED] A nucleic acid encoding [a] the protein of [as defined in] claim

13.

REMARKS

Applicants respectfully request entry of the above amendments before calculation of fees for filing of the attached national phase application under 37 U.S.C. § 371.

Respectfully Submitted,
LYON & LYON LLP

By: 

Kurt T. Mulville
Reg. No. 37,194

Dated: June 21, 2000

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
949/567-2300 X 1124
213/955-0440 Facsimile